Xilio Therapeutics, Inc. (XLO) Free cash flow 2020–2025
Xilio Therapeutics, Inc. (XLO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$5.5MFY2025 · since FY2020: -$38.3M → -$5.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$5.5M | +70.1% |
| FY2024 | -$18.4M | +73.4% |
| FY2023 | -$69.1M | +10.9% |
| FY2022 | -$77.6M | +5.2% |
| FY2021 | -$81.9M | -113.8% |
| FY2020 | -$38.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice